RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Novartis expects to submit 50 new drug applications in China between 2019 and 2023 — ten per year — according to John Tsai, head of global drug development and chief medical officer for Novartis. The new drugs will target major diseases in China, he said, as he praised China’s greatly speeded up regulatory reviews, which now offer timelines similar to the US and EU. “In light of the governmental regulatory reforms, we are working to have every pivotal drug development program include China from the beginning by default,” said Tsai.
Source: China Biotoday
